ATX-304 by Amplifier TX for Cardiometabolic Disease: Likelihood of Approval
ATX-304 is under clinical development by Amplifier TX and currently in Phase I for Cardiometabolic Disease. According to GlobalData, Phase I drugs for Cardiometabolic Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ATX-304 LoA Report. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.ATX-304 overviewATX-304 is under development for the treatment of cardiometabolic disease, non-alcoholic fatty liver disease, obesity, heart failure with preserved ejection fraction (HFpEF) (NAFLD)/non-alcoholic steatohepatitis (NASH), peripheral vascular disease, type 2 diabetes. The drug candidate is administered orally and is formulated as suspension for type 2 diabetes. The drug candidate acts by targeting adenosine monophosphate activated protein kinase (AMPK) and proprotein convertase subtilisin/kexin type 9. It was also under development for sarcopenia, cancer and diabetic kidney disease.Amplifier TX overviewAmplifier TX is a biopharmaceutical company that develops AMPK compounds to treat diseases such as cardiovascular, metabolic conditions, diseases, kidney diseases and cancer. The company is headquartered in New York, the US. For a complete picture of ATX-304's drug-specific PTSR and LoA scores, buy the report here.
ATX-304 is under clinical development by Amplifier TX and currently in Phase I for Cardiometabolic Disease.
What's Your Reaction?
